Immunology and Infectious Diseases
We're advancing innovative science and transformative medicines for people living with inflammatory and autoimmune diseases, including a portfolio of first in class programs and innovative development approaches across inflammatory bowel disease (IBD) and respiratory, and rheumatological diseases.
In addition, we’re committed to help find effective treatments for life-threatening infectious diseases, with a leading portfolio in hepatitis B, influenza and multi-drug resistant bacterial infections.
Partnering opportunities we are looking for:
- Gastroenterology, Respiratory, Rheumatology
- Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets
- Hep B & Respiratory Viruses
- Multidrug-resistant, Gram-negative Bacterial Infections
Parvus – collaboration to develop, manufacture and commercialise novel Navacim therapeutics to drive tolerance in inflammatory bowel disease, autoimmune liver disease and celiac disease
Jecure – acquisition to combine preclinical portfolio of NLPR3 inhibitors with in-house expertise, discovery and development capabilities in this area